Treats overactive bladder with symptoms of urge urinary incontinence, urgency and…. ANDA 207302, held by Macleods Pharms. Darifenacin Hydrobromide.
As of Nov 16, 2026, ANDA 207302 (Darifenacin), held by Macleods Pharms, was first approved by FDA on Jul 28, 2017, with 0 approved supplements and 0 published complete response letters.
Darifenacin is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 28, 2017 | Original application | Approved | None posted |
| DarifenacinEQ 7.5MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
| DarifenacinEQ 15MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters